Clinical Trial: Continued Access to PREVAIL (CAP2)
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: Continued Access to PREVAIL (CAP2)- WATCHMAN Left Atrial Appendage (LAA) Closure Technology
Brief Summary: To provide additional information about the safety and efficacy of the WATCHMAN LAA Closure Technology
Detailed Summary:
Sponsor: Boston Scientific Corporation
Current Primary Outcome: Incidence of stroke leading to significant disability/death [ Time Frame: up to 5 years ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Boston Scientific Corporation
Dates:
Date Received: November 6, 2012
Date Started: September 2012
Date Completion: February 2019
Last Updated: July 18, 2016
Last Verified: July 2016